Atopic dermatitis and inflammatory skin diseaseProgression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses
Section snippets
Skin biopsies and RNA-sequencing
Intrapersonal acute, chronic (>72-hour duration), and nonlesional (≥10 cm from active lesions) skin biopsies were collected from 11 consented white patients with moderate to severe AD, along with biopsies from 38 healthy volunteers included in a previous skin transcriptome study8 under an Institutional Review Board–approved protocol (A110/12) (see Table E1 in this article’s Online Repository at www.jacionline.org). In all patients, biopsies were taken from the upper arms (flexural side). No
Results
We performed RNA-sequencing on biopsies from nonlesional and paired acute and chronic lesions, enabling us to conduct robust analysis of differences and potential progression from nonlesional to acute to chronic stages of inflammation. We were able to profile 31,207 genes with an average of at least 1 read/sample. Notably, the top 3 principal components were not able to separate acute from chronic AD (Fig 1, A). A previous microarray-based study using less stringent criteria (ie, |log2 FC| ≥
Discussion
Clinically, AD presents with eczematous lesions in different acuity stages. Acute and chronic lesions are often found in the same individual, often overlap, and clinically are sometimes difficult to distinguish.24 Histologically, acute and chronic AD have fairly distinctive features. For instance, acute AD lesions exhibit spongiosis with mild to moderate acanthosis in addition to a superficial perivascular infiltrate of lymphocytes and macrophages. Mast cells show degranulation,25 and
References (42)
- et al.
Clinical onset of atopic eczema: results from 2 nationally representative British birth cohorts followed through midlife
J Allergy Clin Immunol
(2019) - et al.
Cellular and molecular mechanisms in atopic dermatitis
Adv Immunol
(2009) - et al.
Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
J Allergy Clin Immunol
(2012) - et al.
Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis
J Invest Dermatol
(2019) - et al.
Identification of human hornerin and its expression in regenerating and psoriatic skin
J Biol Chem
(2005) - et al.
The cartilage-specific lectin C-type lectin domain family 3 member A (CLEC3A) enhances tissue plasminogen activator-mediated plasminogen activation
J Biol Chem
(2018) - et al.
The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases
J Allergy Clin Immunol
(2016) - et al.
Role of vasculature in atopic dermatitis
J Allergy Clin Immunol
(2006) - et al.
Atopic dermatitis
Lancet
(2016) - et al.
IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells
J Allergy Clin Immunol
(2009)
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab
J Allergy Clin Immunol
Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments—a randomized, double-blind, phase 2a trial
J Am Acad Dermatol
Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells
J Allergy Clin Immunol
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial
J Am Acad Dermatol
IL-10-producing regulatory B cells are decreased in patients with atopic dermatitis
J Invest Dermatol
Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis
J Allergy Clin Immunol
Noncanonical pathway for regulation of CCL2 expression by an mTORC1-FOXK1 axis promotes recruitment of tumor-associated macrophages
Cell Rep
FOXE1 inhibits cell proliferation, migration and invasion of papillary thyroid cancer by regulating PDGFA
Mol Cell Endocrinol
What’s new in atopic eczema? An analysis of systematic reviews published in 2016, part 2: epidemiology, aetiology and risk factors
Clin Exp Dermatol
The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies
Allergy
Atopic dermatitis
Nat Rev Dis Primers
Cited by (101)
Emerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin Diseases
2024, Journal of Investigative DermatologyDiversity of atopic dermatitis and selection of immune targets
2024, Annals of Allergy, Asthma and ImmunologyThe epidermal lipid-microbiome loop and immunity: Important players in atopic dermatitis
2024, Journal of Advanced ResearchGene Expression Signatures in Inflammatory and Sclerotic Morphea Skin and Sera Distinguish Morphea from Systemic Sclerosis
2023, Journal of Investigative DermatologyProbiotic-fermented Portulaca oleracea L. alleviated DNFB-induced atopic dermatitis by inhibiting the NF-κB signaling pathway
2023, Journal of Ethnopharmacology
This work was supported by BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis), a project funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement number 821511 and in-kind contributions of the participating pharma companies. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. It further received support from the Babcock Endowment Fund (L.C.T., M.K.S., J.E.G.), the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award numbers R01-AR060802 (J.E.G.), P30-AR075043 (J.E.G.), and K01-AR072129 (L.C.T.), and the National Institute of Allergy and Infectious Diseases under award number R01-AR069071 (J.E.G.), the A. Alfred Taubman Medical Research Institute (J.E.G. and J.M.K.), and the Kenneth and Frances Eisenberg Emerging Scholar Award (J.E.G.). L.C.T. is supported by the Dermatology Foundation, the Arthritis National Research Foundation, and the National Psoriasis Foundation. Infrastructure support was provided through the DFG Cluster of Excellence ‘‘Precision Medicine in Inflammation’’ (grant no. EXC2167).
Disclosure of potential conflict of interest: J. M. Kahlenberg serves as advisory boards and received consulting fees from AstraZeneca, BMI, BMS, and Eli Lilly, and also received grant funding from Celgene/BMS. J. E. Gudjonsson received research grants from AbbVie, AnaptysBio, Pfizer, Novartis, Celgene, and Eli Lilly, and serves as advisory board member in Novartis, AbbVie, Eli Lilly, MiRagen, and Almirall. S. Weidinger has received institutional research grants from Novartis, Pfizer, and L’Oreal; has performed consultancies for Sanofi-Genzyme, Regeneron, LEO Pharma, Incyte, Lilly, AbbVie, and Novartis; has lectured at educational events sponsored by Sanofi-Genzyme, Regeneron, LEO Pharma, AbbVie, and Galderma; and is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of atopic dermatitis. The rest of the authors declare that they have no relevant conflicts of interest.